Cytosorbents Corporation (CTSO) Expected to Post Earnings of -$0.09 Per Share
Equities research analysts expect that Cytosorbents Corporation (NASDAQ:CTSO) will announce earnings per share of ($0.09) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Cytosorbents Corporation’s earnings, with the highest EPS estimate coming in at ($0.07) and the lowest estimate coming in at ($0.11). Cytosorbents Corporation reported earnings per share of ($0.11) in the same quarter last year, which suggests a positive year over year growth rate of 18.2%. The business is scheduled to report its next quarterly earnings results on Monday, November 6th.
According to Zacks, analysts expect that Cytosorbents Corporation will report full-year earnings of ($0.29) per share for the current fiscal year, with EPS estimates ranging from ($0.40) to ($0.21). For the next financial year, analysts anticipate that the business will post earnings of ($0.33) per share, with EPS estimates ranging from ($0.52) to ($0.14). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Cytosorbents Corporation.
Cytosorbents Corporation (NASDAQ:CTSO) last released its quarterly earnings results on Monday, August 7th. The medical research company reported ($0.04) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.02. The business had revenue of $3.57 million during the quarter, compared to analysts’ expectations of $3.29 million. Cytosorbents Corporation had a negative return on equity of 529.95% and a negative net margin of 80.56%.
Several equities research analysts have issued reports on CTSO shares. Aegis restated a “buy” rating and set a $9.00 target price on shares of Cytosorbents Corporation in a research report on Tuesday, May 9th. Maxim Group set a $10.00 target price on Cytosorbents Corporation and gave the stock a “buy” rating in a research report on Monday, May 22nd. Cowen and Company started coverage on Cytosorbents Corporation in a research report on Wednesday, June 7th. They set an “outperform” rating and a $7.00 target price on the stock. B. Riley restated a “buy” rating and set a $11.25 target price on shares of Cytosorbents Corporation in a research report on Monday, August 7th. Finally, HC Wainwright set a $13.00 target price on Cytosorbents Corporation and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Six equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus target price of $12.71.
In related news, insider Phillip P. Chan bought 6,300 shares of the company’s stock in a transaction on Monday, June 5th. The shares were purchased at an average price of $4.00 per share, for a total transaction of $25,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders have acquired 16,500 shares of company stock worth $66,280. Company insiders own 5.60% of the company’s stock.
Several large investors have recently modified their holdings of the company. Skylands Capital LLC increased its stake in shares of Cytosorbents Corporation by 87.7% in the second quarter. Skylands Capital LLC now owns 594,250 shares of the medical research company’s stock worth $2,555,000 after buying an additional 277,650 shares during the period. Sabby Management LLC acquired a new stake in shares of Cytosorbents Corporation during the first quarter worth about $990,000. Cowen Group Inc. acquired a new stake in shares of Cytosorbents Corporation during the first quarter worth about $248,000. PNC Financial Services Group Inc. increased its stake in shares of Cytosorbents Corporation by 145.2% in the second quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock worth $163,000 after buying an additional 22,500 shares during the period. Finally, Segantii Capital Management Ltd increased its stake in shares of Cytosorbents Corporation by 563.4% in the first quarter. Segantii Capital Management Ltd now owns 27,200 shares of the medical research company’s stock worth $122,000 after buying an additional 23,100 shares during the period. Institutional investors own 9.63% of the company’s stock.
Cytosorbents Corporation (CTSO) remained flat at $4.75 during mid-day trading on Friday. The company had a trading volume of 37,267 shares. The firm’s market cap is $133.63 million. Cytosorbents Corporation has a 52-week low of $3.30 and a 52-week high of $6.90. The stock’s 50 day moving average price is $4.78 and its 200-day moving average price is $4.83.
About Cytosorbents Corporation
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with MarketBeat.com's FREE daily email newsletter.